Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases

Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases

Abstract Background Antiangiogenic therapy has proved to be an important therapeutic tool for many retinal vascular diseases; however, its availability is limited in developing countries. This study sought to describe the bevacizumab vial sharing process and to evaluate the impact of this repackagin...

Full description

Bibliographic Details
Main Authors: Sávio Lima Sodré, Italo Antunes França Barbosa, Israel Emiliano Pacheco, Felipe de Queiroz Tavares Ferreira, Milton Agrizzi David, Mauricio Abujamra Nascimento, Carlos Eduardo Leite Arieta, Jose Paulo Cabral de Vasconcellos
Format: Article
Language:English
Published: BMC 2019-09-01
Series:BMC Public Health
Subjects:
Anti-vascular endothelial growth factor
Bevacizumab
Repackaging
Vial sharing
Public hospitals
Brazil
Online Access:http://link.springer.com/article/10.1186/s12889-019-7562-y

Internet

http://link.springer.com/article/10.1186/s12889-019-7562-y

Similar Items